Date: 2016-01-22
Type of information: Nomination
Compound:
Company: Cellaviva (Sweden)
Therapeutic area: Regenerative medicine
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 22, 2016, Diamyd Medical announced that its CEO, Anders Essen-Möller is proposed as new Chairman of the Board of Cellaviva AB at Cellaviva’s Annual General Meeting, February 18, 2016. Diamyd Medical is the largest shareholder of Cellaviva AB, Sweden’s first biobank for family saving and research on stem cells from the umbilical cord.
Financial terms:
Latest news:
